Zacks.com on MSN14h
NVO Stock Rises as New Obesity Drug Shows Superior Weight LossShares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback